Roche Holding AG

RHHBY | OTC

Price Alert Chart Builder DCF Calculator

$55.34

+$1.19 (+2.20%)

At close: Sep 21, 2026, 3:59 PM ET

$55.30

-$0.04 (-0.07%)

After-hours: Sep 21, 2026, 4:00 PM ET

Overview Rating Statistics Financials Earnings Ownership Dividends Profile

+2.20%

(1D)

Rating

Updated: Sep 17, 2026

54.2

Fundamentals Average

Market Sentiment Bullish

Moat Wide

Full Analysis

Key Statistics

Market Data

Market Cap $352.77B

1D Range

55.09 55.63

52W Range

39.50 60.85

Valuation (TTM)

PE 53.87

PB 9.75

EV/EBITDA 24.05

Valuation (NTM)

Forward PE 16.45

Forward PEG 2.60

Price Target $63

Cash Flow

FCF Yield 4.3%

SBC Adj. FCF Yield 4.3%

SBC Impact -1.6%

Margins

Gross Margin 73.5%

Operating Margin 28.4%

FCF Margin 27.0%

Growth (CAGR)

Revenue 3Y | 5Y -9.0% | -1.5%

Dil EPS 3Y | 5Y -19.6% | -7.3%

FCF 3Y | 5Y -8.1% | 1.7%

Returns

ROA 12.8%

ROE 41.2%

ROIC 20.3%

Financial Health

Net Debt

CHF21.01B ($26.49B)

Current Ratio 1.38

Interest Coverage 14.28

Dividends

Div Yield 2.80%

Payout Ratio 174.1%

FCF Payout Ratio 30.7%

All Key Statistics

Loading financial charts...

Profile

A detailed description of the company is not yet available.

Sector n/a

Industry n/a

Employees n/a

IPO Date n/a

Website n/a

Fiscal Year n/a

Full Company Profile

Latest News

4 hours ago · wsj.com

Roche Says Drug Helped Patients Reduce Blood-Sugar Levels, Weight in Trial

The results for enicepatide reinforce the company's ambitions to rapidly develop its portfolio of medicines for people with obesity, diabetes and cardiovascular disease.

4 days ago · zacks.com

RHHBY's Lunsumio Combo Meets Goal in 2L Follicular Lymphoma Study

Roche's Lunsumio-Revlimid combo meets its study goal in second-line or later follicular lymphoma, improving PFS versus rituximab plus Revlimid.

11 months ago · businesswire.com

Positive Phase III Results for Genentech's Gazyva in Children and Young Adults With Idiopathic Nephrotic Syndrome

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today statistically significant and clinically meaningful results from the Phase III INShore study of Gazyva® (obinutuzumab) in children and young adults (aged ≥ 2-25 years) with idiopathic nephrotic syndrome (INS). The study met its primary endpoint, with more people achieving sustained complete remission at one year (week 52) with Gazyva compared with mycophenolate mofet.

Earnings

Next Earnings

Feb 4, 2027

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞